Aligos Therapeutics
ALGS
31 hedge funds and large institutions have $13.2M invested in Aligos Therapeutics in 2026 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 9 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
8.96% less ownership
Funds ownership: 51.51% → 42.55% (-9%)
11% less funds holding
Funds holding: 35 → 31 (-4)
36% less capital invested
Capital invested by funds: $20.6M → $13.2M (-$7.39M)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$343K |
| 2 |
Jane Street
New York
|
+$200K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$142K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$130K |
| 5 |
BlackRock
New York
|
+$107K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$1.71M |
| 2 |
SC
SummitTX Capital
Fort Worth,
Texas
|
-$1.11M |
| 3 |
Renaissance Technologies
New York
|
-$554K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$404K |
| 5 |
LPL Financial
San Diego,
California
|
-$383K |
ALGS Hedge Fund Activity: Q2 2026 in Review
31 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q2 2026, worth a combined $13.2M — down 36% from $20.6M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ALGS and 5 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 7 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $343K. The largest seller was Bank of America, exiting entirely with an estimated $1.71M sold.
- 31 institutional investors held Aligos Therapeutics (ALGS) as of Q2 2026, down from 35 in Q1 2026.
- Funds reported $13.2M of Aligos Therapeutics stock for Q2 2026, down 36% quarter-over-quarter.
- 5 funds opened new Aligos Therapeutics positions in Q2 2026 and 9 closed out, a net change of -4 holders.
- The largest Aligos Therapeutics buyer in Q2 2026 was D.E. Shaw & Co, an estimated $343K added.
- The largest Aligos Therapeutics seller in Q2 2026 was Bank of America, an estimated $1.71M sold.
Based on aggregated 13F filings for Q2 2026.